KIT Expression is a predictive biomarker for use of imatinib in patients.
Of the therapies with KIT Expression as a predictive biomarker, 1 is FDA-approved in at least one clinical setting.
Gastrointestinal stromal tumor has the most therapies targeted against KIT Expression or its related pathways .
Gastrointestinal Stromal Tumor -
Sample must match one or more of the following:
|Predicted Response: Primary Sensitivity|
|Clinical Setting(s): Metastatic (FDA)|
|Note: Imatinib is indicated for patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).|
KIT Expression serves as an inclusion eligibility criterion in 15 clinical trials, of which 11 are open and 4 are closed. Of the trials that contain KIT Expression as an inclusion criterion, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 8 are phase 2 (7 open), and 4 are phase 3 (2 open).
Trials with KIT Expression in the inclusion eligibility criteria most commonly target gastrointestinal stromal tumor, acute myeloid leukemia, and myelodysplastic syndromes .
Imatinib, donor-derived wt1/prame/ny-eso-1/survivin-specific t-lymphocytes, avelumab, axitinib, and azacitidine are the most frequent therapies in trials with KIT Expression as an inclusion criteria .
Significance of KIT Expression in Diseases
Gastrointestinal Stromal Tumor +
KIT is altered in 71.19% of gastrointestinal stromal tumor patients .
KIT Expression is an inclusion criterion in 11 clinical trials for gastrointestinal stromal tumor, of which 9 are open and 2 are closed. Of the trials that contain KIT Expression and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open), 6 are phase 2 (6 open), and 4 are phase 3 (2 open) .
Imatinib has evidence of efficacy in patients with KIT Expression in gastrointestinal stromal tumor .
Acute Myeloid Leukemia +
KIT is altered in 2.0% of acute myeloid leukemia patients .
KIT Expression is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 2 are open and 1 is closed. Of the trials that contain KIT Expression and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) .
Myelodysplastic Syndromes +
KIT is altered in 0.89% of myelodysplastic syndromes patients .
KIT Expression is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain KIT Expression and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) .
Malignant Solid Tumor +
KIT is altered in 3.15% of malignant solid tumor patients .
KIT Expression is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains KIT Expression and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.